AstraZeneca, Teva Settle Byetta Patent LitigationBy
Teva Pharmaceuticals USA has settled patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB, and Amylin Pharmaceuticals, LLC relating to AstraZeneca's US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca's Byetta (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of Byetta described in Teva's abbreviated new drug application in the United States. Byetta is used to treat Type II diabetes.
The settlement allows Teva to commercialize its generic version of Byetta (exenatide injection) in the US beginning October 15, 2017 or earlier under certain circumstances. All other terms of the agreement are confidential.
Byetta posted 2015 sales of $316 million.
Source: Teva Pharmaceutical Industries